Hummingbird Bioscience

HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new therapy for VISTA-expressing cancers including triple-negative breast cancer and non-small cell lung cancer HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as … Read more

Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 mAb, in combination with cetuximab, an anti-EGFR mAb, in sqNSCLC HMBD-001 used as monotherapy and in combination with cetuximab has been shown to effectively inhibit tumor growth across various preclinical squamous cell carcinoma models SAN FRANCISCO, … Read more